19 institutions hold shares in AzurRx BioPharma Inc. (AZRX), with 763.75k shares held by insiders accounting for 1.03% while institutional investors hold 2.63% of the company’s shares. The shares outstanding are 71.01M, and float is at 29.60M with Short Float at 2.26%. Institutions hold 2.61% of the Float.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 0.69 million shares valued at $0.67 million. The investor’s holdings represent 1.05% of the AZRX Shares outstanding. As of Dec 30, 2020, the second largest holder is Bank Of New York Mellon Corporation with 0.43 million shares valued at $0.42 million to account for 0.66% of the shares outstanding. The other top investors are Renaissance Technologies, LLC which holds 0.19 million shares representing 0.29% and valued at over $0.18 million, while Parsons Capital Management, Inc. holds 0.26% of the shares totaling 0.17 million with a market value of $0.16 million.
AzurRx BioPharma Inc. (NASDAQ: AZRX) is 5.15% higher on its value in year-to-date trading and has touched a low of $0.51 and a high of $2.63 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AZRX stock was last observed hovering at around $1.34 in the last trading session, with the day’s loss setting it -0.32% off its average median price target of $3.00 for the next 12 months. It is also 79.6% off the consensus price target high of $5.00 offered by 4 analysts, but current levels are 59.2% higher than the price target low of $2.50 for the same period.
Currently trading at $1.02, the stock is -24.09% and -32.08% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 16.55 million and changing -23.88% at the moment leaves the stock 1.73% off its SMA200. AZRX registered 79.26% gain for a year compared to 6-month gain of 43.46%. The firm has a 50-day simple moving average (SMA 50) of $1.4174 and a 200-day simple moving average (SMA200) of $1.0485.
The stock witnessed a -21.54% loss in the last 1 month and extending the period to 3 months gives it a -1.92%, and is -24.44% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.00% over the week and 11.24% over the month.
Distance from 52-week low is 99.92% and -61.22% from its 52-week high.
AzurRx BioPharma Inc. (AZRX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for AzurRx BioPharma Inc. (AZRX) is a “Overweight”. 4 analysts offering their recommendations for the stock have an average rating of 2.20, where 1 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
AzurRx BioPharma Inc. is expected to release its quarterly report on 08/10/2021 and quarterly earnings per share for the current quarter are estimated at -$0.09.The EPS is expected to grow by 22.80% this year
AzurRx BioPharma Inc. (AZRX) Insider Activity
A total of 0 insider transactions have happened at AzurRx BioPharma Inc. (AZRX) in the last six months, with sales accounting for 0 and purchases happening 0 times.
AzurRx BioPharma Inc. (AZRX): Who are the competitors?
The company’s main competitors (and peers) include Pieris Pharmaceuticals Inc. (PIRS) that is trading 25.73% up over the past 12 months. Short interest in the company’s stock has fallen -239.27% from the last report on Feb 11, 2021 to stand at a total of 2.27 million short shares sold with a short interest ratio of 0.21.